TAS-116, a highly selective inhibitor of heat shock protein 90α and β, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models

Molecular Cancer Therapeutics

Volumn 14, Issue 1, 2015, Pages 14-22

  Ohkubo, Shuichi ^a   Kodama, Yasuo ^a   Muraoka, Hiromi ^a   Hitotsumachi, Hiroko ^a   Yoshimura, Chihoko ^a   Kitade, Makoto ^a   Hashimoto, Akihiro ^a   Ito, Kenjiro ^a   Gomori, Akira ^a   Takahashi, Koichi ^a   Shibata, Yoshihiro ^a   Kanoh, Akira ^a   Yonekura, Kazuhiko ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 90 INHIBITOR; LUMINESPIB; TAS 116; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; HEAT SHOCK PROTEIN 90; HSP90AB1 PROTEIN, HUMAN; HSP90ALPHA PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; TAS-116;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG EXPOSURE; EYE TOXICITY; HUMAN; HUMAN CELL; MALE; NON SMALL CELL LUNG CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHOTORECEPTOR; PHOTORECEPTOR CELL; PRIORITY JOURNAL; RAT; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG SCREENING; LUNG NEOPLASMS; METABOLISM; MOUSE; PATHOLOGY; RETINA; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MICE; PHOTORECEPTOR CELLS; PYRAZOLES; RATS; RETINA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921260124     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0219     Document Type: Article

References (49)

1. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010;10:537-49.
2. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72.
3. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 2012;18:64-76.
4. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005;10:86-103.
5. Ferrarini M, Heltai S, Zocchi MR, Rugarli C. Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer 1992;51:613-9.
6. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425:407-10.
7. Vilenchik M, Solit D, Basso A, Huezo H, Lucas B, He H, et al. Targeting wide-range oncogenic transformation via PU24FCl, a speci fic inhibitor of tumor Hsp90. Chem Biol 2004;11:787-97.
8. Garcia-Carbonero R, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol 2013;14:e358-69.
9. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, andmetastasis. Cancer Res 2008;68:2850-60.
10. Floris G, Debiec-Rychter M, Wozniak A, Stefan C, Normant E, Faa G, et al. The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors. Mol Cancer Ther 2011;10:1897-908.
11. Lundgren K, Zhang H, Brekken J, Huser N, Powell RE, Timple N, et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther 2009;8:921-9.
12. Smyth T, Van Looy T, Curry JE, Rodriguez-Lopez AM, Wozniak A, Zhu M, et al. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models. Mol Cancer Ther 2012;11:1799-808.
13. Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 2012;11:475-84.
14. Scaltriti M, Dawood S, Cortes J. Molecular pathways: targeting hsp90-who benefits and who does not. Clin Cancer Res 2012;18:4508-13.
15. Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 2012;1823:742-55.
16. Samuni Y, Ishii H, Hyodo F, Samuni U, Krishna MC, Goldstein S, et al. Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs. Free Radic Biol Med 2010;48:1559-63.
17. Saif MW, Takimoto C, Mita M, Banerji U, Lamanna N, Castro J, et al. A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors. Clin Cancer Res 2014;20:445-55.
18. Goldman JW, Raju RN, Gordon GA, El-Hariry I, Teofilivici F, Vukovic VM, et al. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer 2013;13:152.
19. Rajan A, Kelly RJ, Trepel JB, Kim YS, Alarcon SV, Kummar S, et al. A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res 2011;17:6831-9.
20. Renouf DJ, Velazquez-Martin JP, Simpson R, Siu LL, Bedard PL. Ocular toxicity of targeted therapies. J Clin Oncol 2012;30:3277-86.
21. Sessa C, Shapiro GI, Bhalla KN, Britten C, Jacks KS, Mita M, et al. First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res 2013;19:3671-80.
22. Howes R, Barril X,Dymock BW, Grant K, Northfield CJ, Robertson AG, et al. A fluorescence polarization assay for inhibitors of Hsp90. Anal Biochem 2006;350:202-13.
23. Lea WA, Simeonov A. fluorescence polarization assays in small molecule screening. Expert Opin Drug Discov 2011;6:17-32.
24. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099-108.
25. Gabrielsson J, Weiner D. Non-compartmental analysis. Methods Mol Biol 2012;929:377-89.
26. Uno T, Kitade M, Yamashita S, Oshiumi H, Kawai Y, Mizutani T, et al. TAS-116, an orally available HSP90α/β selective inhibitor: synthesis and biological evaluation. Mol Cancer Ther 12:11s, 2013 (suppl; abstr C127).
27. Wu Z, Moghaddas Gholami A, Kuster B. Systematic identi fication of the HSP90 candidate regulated proteome. Mol Cell Proteomics 2012;11:M111016675.
28. Zou J, Guo Y,Guettouche T, Smith DF, Voellmy R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 1998;94:471-80.
29. Liu B, Staron M, Hong F, Wu BX, Sun S, Morales C, et al. Essential roles of grp94 in gut homeostasis via chaperoning canonical Wnt pathway. Proc Natl Acad Sci U S A 2013;110:6877-82.
30. Söderberg O, Gullberg M, Jarvius M, Ridderstra˚le K, Leuchowius KJ, Jarvius J, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 2006;3:995-1000.
31. Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi N, Kitano S. Suppression of tumor growth in human gastric cancer with HER2 over-expression by an anti-HER2 antibody in a murine model. Int J Oncol 2005;27:681-5.
32. Quentmeier H, Reinhardt J, Zaborski M, Drexler HG. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 2003;17:120-4.
33. Zhou D, Liu Y, Ye J, Ying W, Ogawa LS, Inoue T, et al. A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors. Toxicol Appl Pharmacol 2013;273:401-9.
34. Mecklenburg L, Schraermeyer U. An overview on the toxic morphological changes in the retinal pigment epithelium after systemic compound administration. Toxicol Pathol 2007;35:252-67.
35. Eiseman JL, Lan J, Lagattuta TF, Hamburger DR, Joseph E, Covey JM, et al. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother Pharmacol 2005;55:21-32.
36. Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, et al. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res 2012;18:4973-85.
37. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
38. Felip E, Carcereny E, Barlesi F, Gandhi L, Sequist LV, Kim S-W, et al. Phase II activity of the HSP90 inhibitor AUY922 in patients with ALK-rearrenged (ALK+) or EGFR-mutated advanced non-small cell lung cancer (NSCLC). Ann Oncol 2012;23 Suppl 9:4380.
39. Hua Y, White-Gilbertson S, Kellner J, Rachidi S,Usmani SZ, Chiosis G, et al. Molecular chaperone gp96 is a novel therapeutic target of multiple myeloma. Clin Cancer Res 2013;19:6242-51.
40. Patel PD, Yan P, Seidler PM, Patel HJ, Sun W, Yang C, et al. Paralog-selective Hsp90 inhibitors define tumor-specifi c regulation of HER2. Nat Chem Biol 2013;9:677-84.
41. Chen WT, Tseng CC, Pfaffenbach K, Kanel G, Luo B, Stiles BL, et al. Liverspecific knockout of GRP94 in mice disrupts cell adhesion, activates liver progenitor cells, and accelerates liver tumorigenesis. Hepatology 2014;59: 947-57.
42. Lee AS, Chen WT. The Yin and Yang of GRP94 in liver tumorigenesis. Hepatology. 2014 Aug 30. [Epub ahead of print].
43. Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone MG, et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005;7:457-68.
44. Rasola A, Neckers L, Picard D. Mitochondrial oxidative phosphorylation TRAP(1)ped in tumor cells. Trends Cell Biol 2014;24:455-63.
45. Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, et al. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res 2011;17:1561-70.
46. Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, et al. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 2006;12:6087-93.
47. Sequist LV, Gettinger S, Senzer NN, Martins RG, Janne PA, Lilenbaum R, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly de fined non-small-cell lung cancer. J Clin Oncol 2010;28:4953-60.
48. Mahadevan D, Rensvold DM, Kurtin SE, Cleary JM, Gandhi L, Lyons JF, et al. First-in-human phase I study: Results of a second-generation non-ansamycin heat shock protein 90 (HSP90) inhibitor AT13387 in refractory solid tumors. J Clin Oncol 30:15s, 2012 (suppl; abstr 3028).
49. Aguila M, Bevilacqua D, McCulley C, Schwarz N, Athanasiou D, Kanuga N, et al. Hsp90 inhibition protects against inherited retinal degeneration. Hum Mol Genet 2013;23:2164-75.